Endometrial Cancer Drug Reduced Death Risk by 32% in Phase 3 Trial
Endometrial Cancer Drug Reduced Death Risk by 32% in Phase 3 Trial Technology Networks
Онкология
🎗️Лента новостей
Онкология
Vall d’Hebron recognised by the OECI as a Comprehensive Cancer Centre with Research Excellence
Vall d’Hebron recognised by the OECI as a Comprehensive Cancer Centre with Research Excellence VHIO
Онкология
What a cancer survivor sees that AI could miss in trial design
What a cancer survivor sees that AI could miss in trial design Pharma Voice
Онкология
STTT: фруктовый сахар способен подавлять развитие рака печени – ОСН
STTT: фруктовый сахар способен подавлять развитие рака печени – ОСН Общественная служба новостей
Онкология
Iza-bren удвоил время до прогрессирования рака легкого с мутацией EGFR
Iza-bren удвоил время до прогрессирования рака легкого с мутацией EGFR the Pharma Media
🎗️
Онкология
As ADC king Enhertu rewrites HER2 breast cancer care, the hunt for what comes next is barely out the gate
As ADC king Enhertu rewrites HER2 breast cancer care, the hunt for what comes next is barely out the gate Fierce Biotech
Онкология
Combining 2 VEGF-Blocking Targeted Therapies Significantly Boosted Survival in Kidney Cancer Study | Newswise
Combining 2 VEGF-Blocking Targeted Therapies Significantly Boosted Survival in Kidney Cancer Study | Newswise Newswise
🎗️
Онкология
Онкологи Кировской области призывают проверить здоровье почек - Re-port.ru
Онкологи Кировской области призывают проверить здоровье почек Re-port.ru
Онкология
Preclinical research shows macrophages can be programmed to fight solid cancer tumors
One person dies every 50 seconds in the U.S. from cancer, and an estimated 39% of people in the country will develop cancer during their lifetime. Survival rates have improved in recent decades from innovations and combinations of treatments, including surgery, chemotherapy, radiation, immunotherapy and biotechnology…
Онкология
How Oncology Nurses Can Overcome Common Barriers to Research
How Oncology Nurses Can Overcome Common Barriers to Research Oncology Nursing News
Онкология
Диварасиб превзошел соторасиб и адаграсиб по общей выживаемости при KRAS G12C-мутантном раке легкого
Диварасиб превзошел соторасиб и адаграсиб по общей выживаемости при KRAS G12C-мутантном раке легкого the Pharma Media
Онкология
Study: Tucatinib substantially delays progression of breast cancer that has spread to the brain
Study: Tucatinib substantially delays progression of breast cancer that has spread to the brain Duke School of Medicine
Онкология
Combining 2 VEGF-Blocking Targeted Therapies Significantly Boosted Survival in Kidney Cancer Study
Combining 2 VEGF-Blocking Targeted Therapies Significantly Boosted Survival in Kidney Cancer Study Roswell Park Comprehensive Cancer Center